Skip to content
Government NSW, Medical Health Aged Care

Common sense needed on medicinal cannabis reform

Unions NSW < 1 mins read

The NSW Government should expedite reforms to treat medicinal cannabis the same way as any other medicine for motorists.

Thousands of workers across NSW who are legally prescribed medicinal cannabis must currently choose between taking their medication as prescribed by their doctor, or keeping their driver's licence and their job.

In its response to the Drug Summit, the NSW Government has today committed to "investigating a medical defence for people using medically prescribed cannabis who are driving: by considering the recommendations due to be provided by an expert working group which is assessing the evidence, reform options, safeguards and whole of government implementation considerations."

Unions NSW Secretary Mark Morey said the solution was more straightforward – amend the Road Transport Act to treat medicinal cannabis like any other prescription medication.

"We should focus on impairment, not presence," Morey said. "Police are already highly trained to detect impaired drivers. If someone is driving while impaired by any substance, they should be off the road. But unimpaired patients following their doctor's orders shouldn't face court summons or potentially lose their livelihoods.

"Workers and their families can't wait for another expert working group while they're forced to choose between managing their medical conditions and paying their bills. The solution to this problem is straightforward."


Contact details:

Nick Lucchinelli 0422 229 032

More from this category

  • Medical Health Aged Care
  • 22/01/2026
  • 23:11
Concept Medical Inc.

Concept Medical Announces First Patient Enrollment in STARS DAPT Randomized Clinical Trial Evaluating Abluminus NP Polymer-Free DES

TAMPA, Fla.–BUSINESS WIRE– Concept Medical Inc., a global pioneer in innovative drug delivery technology, is proud to announce the successful enrollment of the first…

  • Contains:
  • Medical Health Aged Care
  • 22/01/2026
  • 22:11
Sinovac Biotech Ltd.

SINOVAC Announces Nasdaq Hearings Panel Grants Continued Listing

BEIJING--BUSINESS WIRE-- Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the Nasdaq Hearings Panel (the “Panel”) has granted the Company’s request to continue its listing on the Nasdaq Stock Market, subject to stated conditions focused on timely completion of its financial audit and remediation of filing delinquencies. Under the Panel’s decision, SINOVAC must, on or before May 11, 2026, demonstrate compliance with Nasdaq Listing Rule 5250(c)(1) and Listing Rule 5250(c)(2) by completing filings of its annual report for the year ended December 31, 2024 on Form 20-F and…

  • Medical Health Aged Care
  • 22/01/2026
  • 17:11
Galderma

IMCAS 2026: Galderma Showcases the Latest Scientific Advances Behind the Industry’s Broadest Injectable Aesthetics Portfolio

At IMCAS 2026, Galderma will present findings supporting Sculptra’s® regenerative properties and benefits on the body, including improving cellulite appearance, firmness, lift, projection, and…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.